AUPH: Aurinia Pharmaceuticals, Inc.
About
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Current Value
$8.071 Year Return
Current Value
$8.071 Year Return
Key Details
Market Cap
$1.16B
P/E Ratio
-51.46
1Y Stock Return
-6.98%
1Y Revenue Growth
38.72%
Dividend Yield
0.00%
Price to Book
3.0
Strategies that include AUPH
Stock's related to AUPH
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FSLY | 47.02% | $941.41M | -61.50% | 0.00% |
| HBI | 41.85% | $2.92B | +111.51% | 0.00% |
| SABR | 40.73% | $1.41B | -0.81% | 0.00% |
| UPWK | 39.67% | $2.00B | +9.38% | 0.00% |
| YETI | 39.41% | $3.22B | -10.71% | 0.00% |
| HLF | 37.70% | $778.11M | -38.09% | 0.00% |
| TWLO | 37.59% | $14.78B | +54.09% | 0.00% |
| PENN | 37.16% | $3.10B | -19.87% | 0.00% |
| NUS | 35.47% | $377.31M | -55.82% | 7.56% |
| UA | 35.32% | $3.71B | +18.70% | 0.00% |
| WST | 35.23% | $22.02B | -13.73% | 0.27% |
| FARO | 34.30% | $486.17M | +40.51% | 0.00% |
| FRSH | 34.23% | $4.39B | -20.05% | 0.00% |
| BCRX | 34.20% | $1.49B | +41.37% | 0.00% |
| BIGC | 34.13% | $473.42M | -31.75% | 0.00% |
| WWW | 33.31% | $1.79B | +171.57% | 1.80% |
| UAA | 32.89% | $4.06B | +23.88% | 0.00% |
| SRAD | 32.55% | $5.18B | +75.20% | 0.00% |
| IRDM | 31.91% | $3.11B | -25.13% | 1.97% |
| MTW | 31.40% | $353.03M | -29.67% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OCFT | -0.05% | $80.95M | -30.38% | 0.00% |
| BYND | -0.08% | $318.19M | -22.91% | 0.00% |
| DXYZ | 0.11% | - | - | 0.00% |
| MMC | 0.12% | $108.41B | +10.89% | 1.37% |
| SEG | -0.20% | $319.72M | +12.41% | 0.00% |
| CNC | 0.20% | $29.19B | -21.56% | 0.00% |
| NOC | 0.21% | $71.54B | +4.23% | 1.60% |
| FDUS | -0.23% | - | - | 8.29% |
| DK | -0.24% | $1.14B | -34.04% | 5.64% |
| GRPN | -0.24% | $353.14M | -10.75% | 0.00% |
| COKE | -0.27% | $10.72B | +73.12% | 0.33% |
| MNST | 0.28% | $52.25B | -1.95% | 0.00% |
| CMTL | -0.30% | $84.44M | -76.16% | 0.00% |
| AIFU | 0.31% | $67.49M | -83.02% | 0.00% |
| PRPO | -0.39% | $9.10M | -13.65% | 0.00% |
| YRD | 0.44% | $518.01M | +101.02% | 3.44% |
| ALAR | -0.50% | $89.09M | +158.08% | 0.00% |
| IMRN | -0.58% | $10.31M | -5.04% | 0.00% |
| UVE | 0.60% | $631.63M | +36.40% | 2.86% |
| CVM | -0.65% | $41.17M | -73.98% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PLMR | -22.43% | $2.84B | +79.77% | 0.00% |
| PEGA | -19.40% | $7.36B | +65.88% | 0.14% |
| SHAK | -18.23% | $4.77B | +94.62% | 0.00% |
| NEUE | -15.77% | $40.93M | -34.13% | 0.00% |
| TCTM | -14.36% | $8.10M | -42.99% | 0.00% |
| PLCE | -13.50% | $194.34M | -20.91% | 0.00% |
| CREG | -13.09% | $6.14M | -35.78% | 0.00% |
| IDCC | -12.96% | $4.64B | +83.82% | 0.90% |
| SLVM | -12.70% | $3.55B | +82.37% | 1.72% |
| JMIA | -12.65% | $380.31M | +30.53% | 0.00% |
| MCK | -12.38% | $78.15B | +35.51% | 0.42% |
| ATEX | -11.38% | $617.94M | +5.94% | 0.00% |
| RDDT | -10.78% | $24.08B | +303.41% | 0.00% |
| ACGL | -10.35% | $36.00B | +16.84% | 0.00% |
| SSSS | -10.08% | - | - | 0.00% |
| SFL | -10.01% | $1.55B | -4.05% | 9.77% |
| IBKR | -9.60% | $20.20B | +131.83% | 0.37% |
| STNG | -9.54% | $2.96B | +0.87% | 2.75% |
| KELYA | -9.40% | $504.23M | -32.54% | 2.14% |
| DNOW | -9.01% | $1.52B | +40.10% | 0.00% |
ETF's related to AUPH
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CLOU | 37.99% | $349.39M | 0.68% |
| PBD | 36.24% | $89.54M | 0.75% |
| IVOV | 36.19% | $964.95M | 0.15% |
| PBW | 36.17% | $301.18M | 0.65% |
| PTH | 35.85% | $143.31M | 0.6% |
| XBI | 35.80% | $6.58B | 0.35% |
| GNOM | 35.46% | $70.59M | 0.5% |
| VIOV | 34.91% | $1.44B | 0.15% |
| SPSM | 34.29% | $12.72B | 0.03% |
| IJR | 34.24% | $90.05B | 0.06% |
| IJS | 33.96% | $7.37B | 0.18% |
| IBB | 33.88% | $6.66B | 0.45% |
| KOMP | 33.71% | $2.09B | 0.2% |
| BETZ | 33.69% | $79.19M | 0.75% |
| WCLD | 33.39% | $454.67M | 0.45% |
| RSPA | 32.93% | $273.87M | 0% |
| ARKX | 32.63% | $249.95M | 0.75% |
| IWO | 32.50% | $12.56B | 0.24% |
| IWC | 32.47% | $933.99M | 0.6% |
| XSW | 32.46% | $402.79M | 0.35% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| JBBB | -0.03% | $1.26B | 0.49% |
| ULST | 0.23% | $535.47M | 0.2% |
| XBIL | -0.33% | $637.70M | 0.15% |
| UNG | 0.62% | $908.80M | 1.06% |
| DBMF | 0.75% | $1.02B | 0.85% |
| SHV | -0.75% | $18.13B | 0.15% |
| BOXX | -0.89% | $4.43B | 0.1949% |
| IBTE | -0.90% | $1.70B | 0.07% |
| SGOV | 1.00% | $27.53B | 0.09% |
| IVOL | 1.32% | $548.70M | 1.02% |
| CLOI | 1.39% | $715.40M | 0.4% |
| KRBN | 1.52% | $242.47M | 0.85% |
| JUCY | -1.85% | $324.29M | 0.6% |
| DBO | 2.17% | $217.57M | 0.77% |
| TBIL | 2.33% | $4.38B | 0.15% |
| FTSM | 2.73% | $6.08B | 0.45% |
| FMF | -2.73% | $244.61M | 0.95% |
| BILZ | -2.82% | $563.02M | 0.14% |
| FBY | 2.91% | $127.69M | 0.99% |
| IBTF | 3.69% | $2.05B | 0.07% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -23.91% | $388.04M | 1.43% |
| USDU | -23.82% | $201.97M | 0.5% |
| VIXY | -14.37% | $195.31M | 0.85% |
| UUP | -12.91% | $309.25M | 0.77% |
| GBIL | -10.91% | $5.60B | 0.12% |
| HDRO | -6.27% | $164.26M | 0.3% |
| EQLS | -5.98% | $76.08M | 1% |
| SHYD | -5.94% | $311.50M | 0.35% |
| CTA | -5.85% | $350.27M | 0.78% |
| KMLM | -5.82% | $353.87M | 0.9% |
| CORN | -5.60% | $61.12M | 0.2% |
| TAIL | -5.27% | $67.98M | 0.59% |
| HIGH | -5.04% | $302.78M | 0.51% |
| BSCO | -4.89% | $2.35B | 0.1% |
| SOYB | -4.85% | $27.32M | 0.22% |
| XHLF | -4.76% | $874.27M | 0.03% |
| AGZD | -4.27% | $142.76M | 0.23% |
| DBA | -4.19% | $755.88M | 0.93% |
| BILZ | -2.82% | $563.02M | 0.14% |
| FMF | -2.73% | $244.61M | 0.95% |
News
Yahoo
ROCKVILLE, Md. & EDMONTON, Alberta, November 18, 2024--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Finnhub
ROCKVILLE, EDMONTON - Aurinia Pharmaceuticals Inc. , announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence 2024 taking place in...
Yahoo
ROCKVILLE, Md. & EDMONTON, Alberta, November 15, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE), and reinforce the clinical importance of LUPKYNIS® (v
Yahoo
ROCKVILLE, Md. & EDMONTON, Alberta, November 14, 2024--Aurinia to Participate in Jefferies London Healthcare Conference
Yahoo
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200.
SeekingAlpha
Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued profitability. Read more here.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.